Clinical evaluation of drug-induced hepatitis;Evaluación clínica de las hepatitis producidas por fármacos

Revista Espanola de Enfermedades Digestivas

Volumn 97, Issue 4, 2005, Pages 258-265

  Martí, Lidia ^a   Del Olmo, J A ^a   Tosca, J ^a   Ornia, E ^a   Garcia Torres M L ^a   Serra, M A ^a   Rodriguez F ^a   Lluch, P ^a   Escudero, A ^a   Rodrigo, J M ^a  

^a HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

Author keywords

Acute hepatitis; Clinical characteristics; Drugs; Epidemiology; Evolution

Indexed keywords

ACECLOFENAC; ACETYLSALICYLIC ACID; ALENDRONIC ACID; ALPRAZOLAM; AMILORIDE; ANALGESIC AGENT; ANETHOLE TRITHIONE; ANTIBIOTIC AGENT; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; ANTIMIGRAINE AGENT; ANTINEOPLASTIC AGENT; ANTIPARKINSON AGENT; ANTITHROMBOCYTIC AGENT; ANXIOLYTIC AGENT; ATENOLOL; BROMAZEPAM; CABERGOLINE; CARBAMAZEPINE; CARDIOVASCULAR AGENT; CLARITHROMYCIN; CLAVULANIC ACID; CODEINE; CYCLOPHOSPHAMIDE; DIAZEPAM; DIHYDROCODEINE; DIHYDROERGOTOXINE; DILTIAZEM; ENALAPRIL; FLUDARABINE; FLUNARIZINE; FLUOXETINE; GABAPENTIN; GEMFIBROZIL; GLIBENCLAMIDE; GLIMEPIRIDE; HORMONE; HYPNOTIC AGENT; IBUPROFEN; ISONIAZID; LEVOTHYROXINE; NEUROLEPTIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; NORFLOXACIN; OMEPRAZOLE; ORAL ANTIDIABETIC AGENT; PARACETAMOL; PAROXETINE; PRAVASTATIN; PSYCHOTROPIC AGENT; PYRAZINAMIDE; QUINAPRIL; RABEPRAZOLE; RANITIDINE; RIFAMPICIN; ROFECOXIB; SEX HORMONE; STOMACH SECRETION INHIBITOR; STREPTOMYCIN; TAMOXIFEN; TIBOLONE; TICLOPIDINE; TIZANIDINE; TRIFLUSAL; TUBERCULOSTATIC AGENT; VALSARTAN; VASODILATOR AGENT; VENLAFAXINE; VITAMIN; ZOLPIDEM;

ABDOMINAL PAIN; ADULT; AGED; ANAMNESIS; ANOREXIA; ARTHRALGIA; ARTICLE; ASTHENIA; CHRONICITY; CLINICAL FEATURE; CLINICAL OBSERVATION; CONVALESCENCE; DRUG WITHDRAWAL; FEMALE; FEVER; FOLLOW UP; HOSPITALIZATION; HUMAN; INCIDENCE; JAUNDICE; LABORATORY DIAGNOSIS; LIVER DISEASE; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; NAUSEA; PROSPECTIVE STUDY; PRURITUS; RETROSPECTIVE STUDY; SEX DIFFERENCE; SIDE EFFECT; SKIN DISEASE; SYMPTOM; TOXIC HEPATITIS; VOMITING;

EID: 19944383848     PISSN: 11300108     EISSN: None     Source Type: Journal    
DOI: 10.4321/S1130-01082005000400006     Document Type: Article

References (17)

1. Lee WM. Drug-Induced Hepatotoxicity. N Engl J Med 2003; 349: 474-85.
2. Bissell D, Gores GJ, Laskin DL, Hoofnagle JH. Drug-Induced liver injury: Mechanisms and test systems. Hepatology 2001; 33: 1009-13.
3. Teschke R. Drug-induced liver diseases. Z Gastroenterol 2002; 40: 305-26.
4. Sachs B, Haider S, Balaraman R, Shahab N, Perri MC. Hepatotoxicity of chemotherapy. Expert Opin Drug Saf 2002; 1: 339-53.
5. Center for Disease Control and Prevention (CDC). Update: adverse event data and revised American Thoracic Society/CDC recommendations against the use of rifampin and pyrazinamide for treatment of latent tuberculosis infection. United States 2003. Morb Mortal Wkly Rep 2003; 52: 735-9.
6. Chan KA, Truman A, Gurwitz JH, Hurley JS, Martinson B, Platt R, et al. A cohort study of the incidence of serious acute liver injury in diabetic patients treated with hypoblycemic agents. Arch Intern Med 2003; 24: 728-34.
7. Sgro C, Clinard F, Ouazir K, Chanay H, Allard C, Guilleminet C, et al. Incidence of drug-induced hepatic injuries: A French population-based study. Hepatology 2002; 36 (2): 451-5.
8. Ibáñiez L, Pérez E, Vidal X, Laporte JR. Prospective surveillance of acute serious liver disease unrelated to infectious, obstructive, or metabolic diseases: epidemiological and clinical features, and exposure to drugs. J Hepatol 2002; 37: 592-600.
9. Larrey D. Drug-induced liver diseases. J Hepatol 2000; 32 (Supl. 1): 77-88.
10. Schencker S, Martin RR, Hoyumpa M. Antecedent liver disease and drug toxicity. J Hepatol 1999; 31: 1098-105.
11. Tegeder I, Levy M, Muth-selbach U, Oelkers R, Neumann F, Dormann H, et al. Retrospective analysis of the frequency and recognition of adverse drug reactions by means of automatically recorded laboratory signals. Br J Clin Pharmacol 1999; 47: 557-64.
12. Bagheri H, Michel F, Lapeyre-Mestre M, Lagier E, Cambus JP, Valdiguié P, et al. Detection and incidence of drug-induced lever injuries in hospital: a prospective analysis from laboratory signals. Br J Clin Pharmacol 2000; 50: 479-84.
13. Arndt, Hawkins D, Anderson JR, Breitfeld P, Womer R, Meyer W. Age is a risk factor for chemotherapy-induced hepatopathy with vincristine, dactinomycin and cyclophosphamide. J Clin Oncol 2004; 22: 1894-901.
14. Friis H, Andreasen PB. Drug-induced hepatic injury: an analysis of 1100 cases reported to the Danish Committee on Adverse Drug Reactions between 1978 and 1987. J Intern Med 1992; 232: 133-8.
15. Hartleb M, Biernat L, Kochel A. Drug-induced liver damage: a three year study of patients for une gastroenterological department. Med Sci Monit 2002; 8: CR292-6.
16. Lucena MI, Camargo R, Andrade RJ, Pérez-Sánchez CJ, Sánchez de la Cuesta F. Comparison of two clinical scales for causality assessment in hepatotoxicity. Hepatology 2001; 33: 123-30.
17. Contreras J, Poniachik J, Planzer M, Lazarte R, Smok G, Oksenberg R, et al. Drug induced liver disease: clinical and pathological pattern in 33 cases. Rev Med Clin 2003; 131: 1128-34.